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Abstract
L-DOPA-induced dyskinesia is a troublesome complication of L-DOPA pharmacotherapy of Parkinson’s disease and has been
associated with disturbed brain opioid transmission. However, so far the results of clinical and preclinical studies on the
effects of opioids agonists and antagonists have been contradictory at best. Prodynorphin mRNA levels correlate well with
the severity of dyskinesia in animal models of Parkinson’s disease; however the identities of the actual neuroactive opioid
effectors in their target basal ganglia output structures have not yet been determined. For the first time MALDI-TOF imaging
mass spectrometry (IMS) was used for unbiased assessment and topographical elucidation of prodynorphin-derived
peptides in the substantia nigra of a unilateral rat model of Parkinson’s disease and L-DOPA induced dyskinesia. Nigral levels
of dynorphin B and alpha-neoendorphin strongly correlated with the severity of dyskinesia. Even if dynorphin peptide levels
were elevated in both the medial and lateral part of the substantia nigra, MALDI IMS analysis revealed that the most
prominent changes were localized to the lateral part of the substantia nigra. MALDI IMS is advantageous compared with
traditional molecular methods, such as radioimmunoassay, in that neither the molecular identity analyzed, nor the specific
localization needs to be predetermined. Indeed, MALDI IMS revealed that the bioconverted metabolite leu-enkephalin-arg
also correlated positively with severity of dyskinesia. Multiplexing DynB and leu-enkephalin-arg ion images revealed small
(0.25 by 0.5 mm) nigral subregions with complementing ion intensities, indicating localized peptide release followed by
bioconversion. The nigral dynorphins associated with L-DOPA-induced dyskinesia were not those with high affinity to kappa
opioid receptors, but consisted of shorter peptides, mainly dynorphin B and alpha-neoendorphin that are known to bind
and activate mu and delta opioid receptors. This suggests that mu and/or delta subtype-selective opioid receptor
antagonists may be clinically relevant for reducing L-DOPA-induced dyskinesia in Parkinson’s disease.
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Introduction
The dopamine (DA) precursor L-DOPA is still the most
effective symptomatic treatment in patients with Parkinson’s
disease (PD), but with time this treatment often causes troublesome
complications, including ‘‘wearing off’’ fluctuations and peak-dose
L-DOPA-induced dyskinesia (LID) [1]. Today many patients
receive DA-agonists instead of L-DOPA as a first line of treatment
of PD in order to reduce the likelihood and delay the development
of LID. However, with time L-DOPA is still required for adequate
symptomatic relief and thus patients suffer a greater risk of
developing LID [2].
Evidence from both clinical studies and experimental models of
Parkinson’s disease link LID to disturbed opioid transmission in
the basal ganglia [3,4]. Several clinical and preclinical studies have
aimed to reduce dyskinesia by using different opioid receptor
antagonists and agonist, but results have been contradictory and
difficult to interpret [4,5,6,7,8,9,10,11,12,13]. In the rat model of
LID in experimental PD, the severity of dyskinesia correlates
strongly with striatal prodynorphin (PDyn or PPE-B) mRNA levels
[14]. But so far no studies have assessed the possible association of
LID with the different prodynorphin peptide products and their
metabolites in the basal ganglia output structures that includes the
substantia nigra (SN).
The exact nature of dynorphin peptides and their metabolites in
the basal ganglia have mostly been studied by means of
radioimmunoassay and immunohistochemistry, which rely on
antibodies to the known molecular species of endogenous
dynorphins and are hampered by possible cross-reactivity with
closely related unknown peptide species [15,16,17,18]. The
prodynorphin propeptide can be processed into several different
neuroactive peptides and several dynorphins have been detected in
the rat substantia nigra by radioimmunoassay; including dynor-
phin A (Dyn A 1-8; Dyn A 1-17), dynorphin B (DynB), alpha- and
beta-neoendorphin (aNeo, bNeo), and leu-enkephalin (Leu-Enk)
[19,20].
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e25653In the current study, a unilateral rat model of PD was treated
with a relative low dose of L-DOPA (8 mg/(kg and day) that is
known to induce LID in some but not all animals. A mass
spectrometry (MS) based imaging technique, MALDI-TOF
imaging MS (MALDI IMS) was used for the detection of
neuropeptides with high molecular weight accuracy and to
determine their distribution in native tissue [21,22] (experimental
set up Fig. 1). For the first time it is possible to demonstrate
alterations in endogenous prodynorphin-derived peptide levels in
the substantia nigra of a model of LID in experimental PD.
Methods
Lesion surgery
Female Sprague-Dawley rats (Scanbur BK AB, Sweden),
weighing 210 to 250 g at the time of surgery were housed four to
a cage in a room with a 12-h light/dark cycle with food and
water ad libitum. The experiments were approved by the Uppsala
animal ethical committee (no 140/8) and followed the guidelines
of Swedish legislation on animal experimentation (Animal
Welfare Act SFS1998:56) and European Union legislation
(Convention ETS123 and Directive 86/609/EEC). Animals
were deeply anesthetized with isoflurane (Apoteksbolaget AB,
Sweden). The toxin 6-OHDA-HCl (Sigma-Aldrich, Germany)
was dissolved in 0.02% ascorbate saline to a concentration of
3.6 mg/ml and injected at the following coordinates in mm
relative to bregma and the dural surface into the right ascending
medial forebrain bundle [23]: (1) anterior -4.4; lateral 1.2;
ventral 7.8; tooth bar at -2.3 (7.5 mg deposit); (2) anterior -4.0;
lateral 0.8; ventral 8.0; tooth bar at +3.4 (6 mgd e p o s i t ) .R i m a d y l
(5 mg/kg, s.c., Apoteksbolaget AB) was used for post-operative
analgesia.
Behavioral tests
The degree of unilateral Parkinsonism was evaluated using the
so-called cylinder test for forelimb-asymmetry use [24,25]. At 3
weeks post lesion, the rats were placed in a glass-cylinder in a new
environment and their forelimb touches to the glass wall (summing
up to 20) were counted as they were rearing to explore the new
environment. Only rats that used their contralateral forelimb less
than 30% of the time were included in this study, corresponding to
approximately 70% striatal DA depletion [25]. L-DOPA treat-
ment and dyskinesia rating started the day after the limb-
asymmetry test. The rats received daily L-DOPA (Sigma-Aldrich)
(8 mg/kg) and benserazide (Sigma-Aldrich) (15 mg/kg) or phys-
iological saline i.p. injections for 15 days and dyskinesia was rated
by a blinded observer every other day according to the dyskinesia
rating scale of Cenci et al. [14]. The rats were observed in
individual cages every 20th minute (1-min monitoring periods)
according to a scale of 0 to 4 for each four categories: 1) limb
dyskinesia, 2) axial dystonia, 3) orolingual movements and 4)
rotational/locomotor behavior. A score of ‘‘0’’ indicate the
absence of abnormal movements. ‘‘1’’ indicates infrequent
dyskinesia that occurred ,50% of the time. ‘‘2’’ indicates
occasional or frequent dyskinetic movement occurring .50% of
the time. ‘‘3’’ specify an incident occurring constantly but can be
interrupted and ‘‘4’’ refer to a constant, uninterruptible dyskinetic
movement.
Figure 1. Experimental design. (A) The experimental set-up consist of unilateral injections of 6-OHDA into the right medial forebrain bundle
anterior of the substantia nigra. A so-called cylinder test was used to assess forelimb asymmetry use and indicated the degree of DA-denervation. L-
DOPA treatment and dyskinesia rating (blue arrow; 8 mg/(kg and day) commenced one day after the first cylinder test and ended one day after the
second test. (B) The brains were dissected out 60 minutes after the last L-DOPA dose. Sections cut on a cryostat were thaw mounted onto MALDI
compatible glass slides and 80 pL-sized drops of MALDI matrix placed in arrays across the sections. (C) Mass spectra were collected from every matrix
spot and assembled into a MALDI imaging MS file that was used to visualize the distribution of different peptides, lipids and small proteins (displayed
in yellow, green, and red).
doi:10.1371/journal.pone.0025653.g001
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PLoS ONE | www.plosone.org 2 September 2011 | Volume 6 | Issue 9 | e25653Forelimb asymmetry use was evaluated a second time, right
before the last and 24 h after the previous L-DOPA administra-
tion.
Pdyn knockout mice. Pdyn
–/– mice were originally obtained
by targeted deletion of the coding exons of the prodynorphin gene
and bred into a 129SvEv-Tac background as described [26].
Animals were housed in groups of up to four per cage with food
and water ad libitum in a room with a 12: 12 h light : dark cycle.
DNA from each animal was extracted for subsequent genotyping
to confirm the identity of the Pdyn locus as described [26] Brain
tissues were isolated from 2 male and 1 female Pdyn knockout
mice following overexposure to halothane and cervical dislocation,
and frozen in liquid nitrogen.
Tissue preparation
60 minutes after the last L-DOPA or saline injection the rats
were deeply anesthetized with isoflurane and decapitated. The
brains were rapidly removed (,30 seconds) and frozen on finely
ground dry ice. Sections for immunohistochemistry were cut at
20 mm and thaw mounted on microscope slides (SuperFrost Plus;
Menzel Glazer, Germany) whereas sections for MALDI-IMS
analysis were cut at 12 mm and thaw mounted on to indium2tin
oxide (ITO)-coated slides (Bruker Daltonics, Germany). The
sections were dehydrated in a vacuum dessicator and stored at
280uC.
Immunohistochemistry
Prior to immunohistochemistry the sections were immersed in
phosphate buffered 4% paraformaldehyd for 2 h at RT, rinsed 3
times in tris-buffered saline and incubated in RTU blocking
solution for 1 h. Immunohistochemistry (TH antiserum diluted
1:1000, MAB318, Millipore, CA; Dyn B, 1:5000, [18] was
performed using a standard peroxidase-based method (RTU
Vectastain kit, Vector laboratories, Burlingame, CA) and 3, 39-
diaminobenzidine (Vector laboratories) as chromogen, or using a
fluorescent secondary antibody (Alexa 488, Invitrogen Co, CA).
Counts of TH-immunopositive cells at three rostrocaudal levels
of SN were carried out by a blinded investigator.
For quantification of dynorphin immunoreactivity the optical
density of the substantia nigra (medial and lateral) was analyzed
with Image J (National Institutes of Health, Bethesda, MD).
MALDI imaging mass spectrometry
In order to fixate tissue and remove salts that interfere with
MALDI, the sections were washed once in 70% (10 seconds) and
twice in 95% ethanol (2 times 10 seconds). The sections were dried
face up in a vacuum desiccator. Matrix (50 mg/ml 2,5-di-
hydroxybezoic acid (DHB) in 50% methanol, 15 mM ammonium
acetate, and 0.3% trifluoroacetic acid (TFA), Sigma-Aldrich)) was
applied using a chemical inkjet printer (CHIP-1000, Shimadzu
Biotech, Japan) and droplets were placed in arrays over SN at a
spatial resolution of 250 mm by 250 mm. The number of droplets
and passes were optimized to 10 drops per pass for 10 passes. Mass
spectra were acquired using an Ultraflex II (Bruker Daltonics,
Germany), equipped with smart beam technology, operating in
reflector positive mode. Each MALDI-adaptor was externally
calibrated using a standard peptide mix (Peptide Calibration
Standard II, Bruker Daltonics). All spectra were processed for
baseline correction (Convex Hull) and exported as .dat-files using
FlexAnalysis (Bruker Daltonics). Total ion current (TIC) normal-
ization was performed on each individual spectrum [27]. Using
Matlab (version R2009b) algorithm msalign and mspeaks available
in Matlab bioinformatic toolpack all spectra were aligned and
peaks with a singal-to-noise ratio .3 were detected. Binning was
performed using a mass spectrometry peak binning software pbin
[28] and the peak area AUC calculated for each peak using an in-
house developed Matlab script. Data is expressed as average peak
area for each area of interest. Animals displaying high degree of
freeze damages to the sections or an uneven TIC, before
normalization, were removed from data analysis, resulting in a
total of 14 duplicate sets of sections per animal (n=4 in LC group,
n=5 and 5 in LD and HD group).
Neuropeptide identification
Opioid peptides were characterized in striatal extracts using a
modified protocol based on strong cation exchange prefractiona-
tion as described previously [16,29]. Briefly, frozen rat brain was
mounted on a cryostat chuck at 220uC, the cortex and corpus
callosum removed and the nucleus accumbens was separated from
the caudate putamen by a thin cut from the most ventral point of
the lateral ventricle to the most ventral point of the external
capsule. Tissue sections (20 mm, n=50 and 50, respectively) were
thaw-mounted on separate superfrost glass slides (Thermo
Scientific, Waltham, MA). Off tissue extraction was performed
by repeated addition and collection of 300 microlitre 5% ACN,
0.1% TFA. The combined extracts were centrifuged at 5000 g for
10 min. The supernatant was collected, applied to small ion
exchange columns (SP C25 Sephadex, GEHealthcare, Uppsala,
Sweden), and eluted stepwise with buffers containing pyridine in
0.1% formic acid (0, 30, 70, and 100% pyridine). The fractions
were dried down under reduced pressure using a speedvac system
(ThermoSavant, Waltham, MA) and stored at 220uC. Prior to
further analysis the fractions were reconstituted in 50 mL 0.1%
formic acid.
Nanoscale liquid chromatography coupled to electrospray
ionization Fourier transform ion cyclotron mass spectrometry
(FTICR MS) was performed on an Agilent 1100 nanoflow system
(Agilent Technologies, Santa Clara, CA, USA) hyphenated to a
LCQ-FT 7.0 (Thermo Scientific). A volume of 5 mL from the
reconstituted SCX fraction was injected automatically and loaded
onto a C18 PicoFrit column (75 mm ID/15 mm tip ID, New-
Objective, Woburn, MA) packed directly inside the electrospray
needle tip using specially designed nanospray emitter tips. A
water/formic acid (FA)/acetonitrile (ACN) solvent system was
used where solvent A was 0.1% FA and solvent B was 100% ACN,
0.1% FA. Gradient elution was performed: 0% B for 10 min, 0%
B to 50% B for 100 min, 50% B to 90% B for 5 min, 90%B for
5 min. Peptide elution was followed by ESI FTICR MS and
tandem mass spectrometry (MS/MS) for peptide sequencing. A
fullscan spectrum was acquired at high resolution (FWHM=
100000) using the FT analyzer. Data dependant acquisition was
applied for MSMS precursor selection, where the 5 most intense
mass peaks were subjected to subsequent isolation and collision-
induced fragmentation in the ion trap. Annotated fragment
spectra were subjected to a database containing sequences of
known rat neuropeptides (SwePep peptides, 245 peptide entries,
www.swepep.org,) and neuropeptide precursor proteins (Swepep
precursor, 123 protein entries) using the Mascot search engine (v
2.2, matrixscience, London, UK). For peptide identification the
search was made with the following specifications: no enzyme
specificity; 10 ppm precursor tolerance and 1.2 Da fragment
tolerance; no fixed modifications; variable modifications: C-term.
amidation, deamidation, oxidation (M); precursor charges: 2+ and
3+; instrument: ESI trap. Peptide matches with a score above the
confidence threshold (p,0.05) were considered to be a significant
hit. The false positive identification rate (FPR) was estimated by
searching the data against a decoy database, where the FPR
threshold was set to ,1%.
Dynorphins in Dyskinesia/PD
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Dyskinesia was evaluated using repeated measurement analysis
of variance (ANOVA), between group differences at particular
time points were tested by Bonferroni post hoc test.
For MALDI IMS data analysis, data was log2 transformed
before further statistical analysis and a linear model was fitted
using both treatment and analyses run as variables. For multiple
testing correction of the p-values the [30] was used. An adjusted p-
value ,0.05 was considered as significant. Statistical analysis was
done using the statistical environment R[31] and the package
Limma [32]. Linear regression was used for its representative
value but Pearson correlation was used to ascertain the nature of
the relationship.
For all statistical comparisons including more than two groups
one-factor ANOVA followed by Tukey post hoc test was used. The
null hypothesis was rejected at p,0.05.
Results
The severity of dyskinesia increases over time
Several rats displayed moderate to high LID on the first L-
DOPA administration and two well separated groups could be
observed; one high dyskinetic group (HD group, n=6) and one
low dyskinetic group (LD group, n=11). The rate of dyskinesia
development per day was similar in both groups (y=mx+b where
m=0.6860.15 and 0.8160.23 for LD and HD group respective-
ly), but the offset was approximately 70 times higher in the HD
group (b=0.41 and 29.94 for LD and HD group respectively;
Fig. 2A). Across the eight dyskinesia scoring sessions the severity of
LID increased in both the LD and the HD group (p,0.0001 for
time effect; p,0.0001 for group effect, no time x group
interaction). Post hoc test revealed significant differences between
the HD and LD group at all time points (p,0.001 HD vs. LD).
Interestingly, even though LD animals displayed a higher peak-
dose dyskinesia score at the end of treatment, no LD animal
became severely dyskinetic during the treatment period (transit
from LD to HD group). From the derived linear equation it may
be possible to predict that it would take on average 42 days using
8 mg/(kg and day) L-DOPA for a low dyskinetic rat to become
high dyskinetic.
Comparing the time course of dyskinesia of the first and last
session revealed that the increase in dyskinesia severity had
developed differently in the LD compared with the HD group
(Fig. 2B, p,0.001 for time x treatment interaction). Post hoc
analysis showed that the peak dose LID score had increased 8-fold
in low dyskinetic rat at 40 and 60 minutes after injection (p,0.01
LD session 8 vs. LD session 1). By contrast, the increase in the HD
group was mainly due to shortened onset latency (p,0.001 HD
session 8 vs. HD session 1).
Low dyskinetic rats show improvements of left forelimb
use
The extent of the lesion was equal in all groups with less than
10% of the number of TH-immunopositive cells remaining in the
lesioned compared with the intact control SN (Fig. 2C). DA-
denervation by injection of the toxin 6-hydroxydopamine (6-
OHDA) into the right medial forebrain bundle is associated with
asymmetric use of the contralateral forelimb. This can be assessed
by placing a rat in a transparent cylinder and registering the
number of occasions that the rat uses the left or right paw to
support its body as it rears to explore a new environment. In the
hemi-parkinsonian rat model used in the present study the left paw
is used to a lesser extent, which is expressed as a percent of the
total number of left and right paw touches to the walls [24].
Neither the %left forelimb use before L-DOPA nor the number of
TH-positive neurons correlated with dyskinesia severity, confirm-
ing other reports that the DA-denervation is a necessary but not
sufficient factor for predicting the rats’ susceptibility to develop
dyskinesias (Putterman et al., 2007).
Forelimb asymmetry use was evaluated a second time before the
last and 24 h after the previous L-DOPA administration.
Interestingly, the %left forelimb use displayed a weak but
significant negative correlation with the cumulative dyskinesia
score (data not shown; p,0.05, Pearson’s correlation coefficient
R=0.52). Comparing the first and last forelimb asymmetry test
revealed that the low-dyskinetic group displayed less forelimb
asymmetry at the second test, whereas the high-dyskinetic group
showed no change and the lesion-only control (LC) group
performed worse than during the first test (p,0.05, LD vs. LC;
Fig. 2D).
MALDI imaging mass spectrometry
The MALDI IMS experiment was repeated twice on consec-
utive sections and over 1000 monoisotopic molecular species
(corresponding to more than 3000 peaks) were detected in the
mass range from 500–3500 Da (Fig. 3A). An overall coefficient of
variance of 30% peak area intensities was observed for all peaks,
but many peaks displayed very low variation (Fig. 3B). For analysis
the SN was divided in 2 halves along a medial-lateral axis
resembling two regions of interests (ROI, Fig. 3C). In each
experiment changes in hundreds of peaks were observed in SN on
the side ipsilateral to the 6-OHDA injection (lesion) relative to the
contralateral (intact) side. For example both decreased (m/z 1481)
and increased peak intensities (m/z 1540) were detected (Fig. 3D).
Here, we focus on LID-associated changes of dynorphin-related
peptides and only significant changes that occurred consistently in
both experiments are reported. Many, but not all, endogenous
dynorphin peptides have previously been identified by MS/MS
analysis from murine brain tissue, including; Dyn A(1-8), aNeo
and Leu-Enk-Arg [33,34]. LC-MS/MS analysis of peptide
extracts was performed in order to obtain peptide identities.
Using high mass accuracy Fourier transform ion cyclotron mass
spectrometry in conjunction with collision activated fragmentation
several dynorphins, including Dyn B could be unequivocally
identified according to its fragment mass data (Supplementary Fig.
S1).
MALDI IMS reveals that dynorphin B peak intensity
correlates with dyskinesia severity
The peak corresponding to Dyn B displayed 44% higher peak
area intensities in the SN ipsilateral to the DA-denervating lesion
of HD animals (Fig. 4A). No side differences in Dyn B peak
intensities were detected in the SN of lesion-only controls or low-
dyskinetic animals. The MALDI ion images revealed that Dyn B
distribution was mainly located to the medial aspect of SN in low-
dyskinetic and lesion control, whereas L-DOPA-induced Dyn B
peak intensity in high-dyskinetic animals was most pronounced in
the lateral tier of SN reaching a 1.75-fold increase on the lesioned
side (Fig. 4B and C, p,0.01 HD vs. LD and LC). Low levels of
Dyn B were also detected in the interpeduncular nucleus and the
part of hippocampus adjacent to the ventral midbrain.
Correlation analysis was carried out in order to assess whether
the severity of dyskinesia was associated with nigral levels of Dyn
B. In the whole SN, Dyn B intensities displayed a weak but
significant correlation to the cumulative dyskinesia score (p ,0.05,
R=0.72). Regional analysis revealed that Dyn B peak intensities
in the lateral SN were positively correlated to the cumulative
dyskinesia score (Fig. 4D, p,0.01, R=0.80), whereas Dyn B peak
Dynorphins in Dyskinesia/PD
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(p=0.30, R=0.36). The Dyn B peak intensities in the lateral SN
correlated equally well with all dyskinesia subtypes individually
(data not shown), but best to the cumulative sum of all dyskinesia
scores. Animals that displayed predominantly axial, limb, and
orolingual dyskinesias had a similar Dyn B distribution in SN as
rats that mainly displayed rotational/locomotive and axial
dyskinesia.
Alpha-neoendorphin peak intensity correlates with
dyskinesia severity
MALDI IMS ion images revealed low aNeo peak intensities in
the SN, interpeduncular nucleus and hippocampus of lesion
control and low-dyskinetic animals (Fig. 5A). Similarly to Dyn B,
aNeo peak intensities were elevated 26% as measured in the whole
medial and lateral part of SN ipsilateral to the DA-denervating
lesion of HD animals. Regional analysis showed that the increase
of aNeo peak intensity (54%) was most pronounced in the lateral
part of SN in high dyskinetic animals compared with the low
dyskinetic and lesion control animals (Fig. 5B; p,0.01 HD vs. LD,
and HD vs. LC). Furthermore, aNeo peak intensity in the lateral
part of SN positively correlated with the cumulative dyskinesia
score reaching a 2-fold difference compared with the intact side in
animals with severe dyskinesia (Fig. 5C; p,0.01; R=0.82).
Similarly to DynB the aNeo intensity in the whole SN displayed
a weaker but still significant correlation (p,0.05, R=0.74)
whereas the intensity in the medial part alone did not correlate
to the cumulative dyskinesia score (p=0.47, R=0.24).
Dynorphin metabolites and dyskinesia
In order to enable the study of dynorphin metabolites with
MALDI IMS, the brains were removed 60 minutes after the last L-
DOPA injection. Several peaks from dynorphin metabolic
fragments displayed significantly higher peak intensities only in
the lateral SN of HD rats, including Leu-Enk-Arg at m/z 712
(Fig. 6A and B; p,0.05 HD vs. LD). The Leu-Enk-Arg ion images
revealed a similar distribution pattern as DynB and aNeo, with
Leu-Enk-Arg mainly localized to SN, interpeduncular nucleus and
the parts of hippocampus flanking the ventral midbrain.
Furthermore, Leu-Enk-Arg peak intensities in the lateral but not
medial part of SN were positively correlated with the cumulative
dyskinesia score (Fig. 6C; p,0.01, R=0.79). Multiplexing the ion
images of both Dyn B and Leu-Enk-Arg revealed that the regional
distribution of the peptides displayed an inverted pattern, as small
regions with elevated Leu-Enk-Arg peak intensity showed
Figure 2. L-DOPA induced dyskinesia. (A) Two well-separated
groups were observed, one high-dyskinetic (HD) and one low-dyskinetic
(LD) group. The rate of dyskinesia development was similar in both
groups, but the on-set was distinctly higher in the HD group. (B) The
increase of dyskinesia score was mainly due to a shorter-onset in the HD
group, and an increase in peak-dose severity in the LD group. (C) The
difference in propensity to develop dyskinesia did not dependent on
the number of remaining TH-immunopositive cells in the lesioned
substantia nigra and was not significantly different between the two
groups or lesion-only controls (LC group) (mean 6 SEM, expressed as %
of TH-immunoreactive neurons in the intact substantia nigra). (D) Low
dyskinetic animals improved the left forelimb asymmetry use in the
second cylinder test, whereas high-dyskinetic animals performed the
same and lesion-only controls worsened. Data is expressed as the
difference between the first and the second cylindertest (*p,0.01 HD
vs. LD group, **p,0.01 session 8 vs. session 1 in HD and LD group,
respectively, ***p,0.001 session 8 vs. session 1, HD group only, #
p=0.01 LC vs. LD).
doi:10.1371/journal.pone.0025653.g002
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of the dorsolateral SN (Fig. 7A).
One putative dynorphin metabolic fragment corresponding to
Leu-Enk-Arg-Arg (m/z 867) was upregulated by 54% in the HD
group compared to the LD group but showed no significant
correlation with LID severity (Fig. 7B; expressed as % of intact
side, mean 6 SEM; HD 170618, LD 110615; p,0.01 HD vs.
LD; p=0.07 and correlation coefficient R=0.59;). Additionally, a
Figure 3. Imaging mass spectrometry. (A) MALDI IMS detects about 3000 peaks throughout the mass range scanned, between 500 to 3500
daltons, corresponding to around 1000 different monoisotopic molecular species. (B,C) Good MALDI IMS reproducibility is displayed as average mass
spectra traces from the intact substantia nigra of low- and high-dyskinetic groups (mean 6 SEM, n=5 and 5 in LD and HD group, respectively). (D)
The ventral midbrain was scanned with MALDI IMS and several different ions were multiplexed in order to define the area of the SN and to divide it
into a medial and a lateral half, by bisecting a line from the ventromedial to the dorsolateral corner of SN. (E) MALDI IMS ion images of two examples
of peptides that displayed a lesion-induced downregulation (red, m/z 1481) or upregulation (green, m/z 1540) in the whole SN (arrows). Abbreviation:
HiC, hippocampus; IPN, interpeduncular nucleus; SN, substantia nigra. Scale bar =2 mm.
doi:10.1371/journal.pone.0025653.g003
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displayed a 45% elevation in peak intensity without a significant
correlation with dyskinesia (Fig. 7C; mean 6 SEM, HD 148612,
LD 102615; p,0.05; p=0.08 and correlation coefficient
R=0.54). Notably, we could not detect any changes in peak
intensities for Dyn A(1–17, m/z 2145), Dyn A(1–8, m/z 981), and
substance P (m/z 1347; Fig. 7 D, E). Leu-Enk (m/z 555) was not
detected in this study most probably due to the limit of detection in
the low molecular weight region. Another way to effectively reduce
opioid receptor activation of dynorphins is by removing the first
N-terminal tyrosine [35]. Metabolic fragments corresponding to
the des-tyrosine forms of Dyn A(1–8), aNeo, and Dyn B were
observed in SN but displayed no treatment-induced changes
(Supplemental Fig. S2).
Figure 4. Dynorphin B peak intensities are elevated in the
lateral SN of high dyskinetic group. (A) Average MS traces show a
higher dynorphin B peak in HD group (average MS 6 SEM, n=5 and 5
in LD and HD group, respectively). (B) MALDI IMS of DynB ion images
of animals from LC (n=4), LD (n=5) and HD (n=5) group. The HD
group display clearly elevated DynB in both high medial and lateral SN
(arrows). (C) The increase in DynB peak intensity was most pronounced
in the lateral tier of SN. Values are expressed as mean % peak area
of intact SN 6 SEM (p,0.01 HD vs. LD, HD vs. LC). (D) Correlation
of Dyn B peak intensities and the cumulative dyskinesia score. Scale
bar=2 mm.
doi:10.1371/journal.pone.0025653.g004
Figure 5. MALDI ion images of alpha-neoendorphin. (A)
Representative MALDI IMS ion images of aNeo. (B) The increase in
aNeo peak intensities were most pronounced in the lateral tier of SN
(arrow). Values are expressed as mean % peak area of intact SN 6 SEM
(*p,0.05 for HD vs. LD, HD vs. LC). (C) Simple regression analysis
of aNeo peak intensities and the cumulative dyskinesia score. Scale
bar=2 mm.
doi:10.1371/journal.pone.0025653.g005
Figure 6. MALDI imaging of Leu-Enk-Arg. (A) Representative
MALDI IMS ion images of and leu-enk-arg. (B) The increase in Leu-Enk-
Arg peak intensities were most pronounced in the lateral tier of SN
(arrow). Values are expressed as mean % peak area of intact SN 6 SEM
(*p,0.05 for HD vs. LD). (C) Simple regression analysis of Leu-Enk-Arg
peak intensities and the cumulative dyskinesia score. Scale bar =2 mm.
doi:10.1371/journal.pone.0025653.g006
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immunoreactivity in the lateral SN
Confirming the MALDI IMS data, Dyn B-immunoreactive
axons densely innervated the substantia nigra and the hippocam-
pus adjacent to the ventral midbrain (cf. Fig. 8 and Fig. 4). In high-
dyskinetic animals, Dyn B immunoreactivity was elevated by 63%
in the lateral SN (Fig. 8B; p,0.001, HD vs. LD, and HD vs. LC
group). A smaller increase by 39% was detected in the medial part
of SN (p,0.05, HD vs. LD, mean % optical density 6 SEM, HD
130613, LD 93 6 8). Indeed, Dyn B immunoreactivity in the
medial part showed a weak but still significant correlation with
cumulative dyskinesia score (p,0.05 R=0.61, data not shown),
however, the strongest correlation was localized to the lateral part
of SN (p,0.001, R=0.83, data not shown). This is strikingly
similar to that observed from the MALDI IMS experiment
(R=0.80, p,0.01). Indeed, a linear correlation between the
MALDI Dyn B peak intensity and the corresponding optical
density of Dyn B immunoreactivity was observed (Fig. 8C;
p,0.05, R=0.73).
Dynorphin peptide validation by IMS of Pdyn knockout
mice
MALDI imaging on striatal sections from wild type control and
Pdyn knockout mice was performed for validation of dynorphin
peptide identities (Fig. 9) [26]. Characteristic high levels were
observed in wild type control mouse nucleus accumbens of several
prodynorphin peptides, for example DynA (10–17), aNeo, DynB,
and the metabolite desTyr-aNeo. Most peptide ion distribution
patterns and levels were not different between wild type control
striatum, for example substance P and PEnk 220–229. By contrast,
no dynorphin peptide peaks could be detected in the striatum of
Pdyn knockout mice (Fig. 9).
Discussion
In the present study we demonstrate that L-DOPA-induced
dyskinesia in a rat model of PD is associated with elevated levels of
Dyn B and aNeo in the lateral, but not medial part of substantia
nigra. Lower peak intensities of other dynorphins, such as Dyn
A(1–8), Dyn A(1–17), and bNeo, were also detected by MALDI
IMS but these were not associated with higher levels in dyskinetic
animals. The predominant presence of aNeo and Dyn B in intact
SN is in accordance with radioimmunoassay measurements from
intact rat SN, where levels of alpha-neoendorphin and Dyn B were
especially high followed by lower levels of Dyn A(1–8) and leu-
enkephalin [16,19,20]. In addition, in the normal intact rat SN
both aNeo and Dyn B peak intensities were particularly high in the
ventromedial tier of SN similar to previously shown by
immunohistochemistry [36]. Immunohistochemical localization
of Dyn B was used as a second means of validation of the IMS
data. Dyn B-immunoreactive axons densely innervated the
substantia nigra with a spatial distribution that corresponded well
to the distribution of the peptide peak as obtained by IMS,
including strong Dyn B immunoreactivity observed in the lateral
SN of high dyskinetic animals. Measurements of optical density of
Figure 7. MALDI IMS ion images of peptides. (A) Composite MALDI IMS ion images from one single section of a high-dyskinetic animal reveal
regional a distinct regional discrepancy between locally low Dyn B (green) and corresponding high Leu-Enk-Arg (red) levels in the dorsolateral SN
(arrow). (B, C) Dynorphin metabolites Leu-Enk-Arg-Arg and aNeo(1–7) were also upregulated in the lateral, but not medial part of SN in HD animals
(arrowhead). (D) Nigral levels of DynA (1–8), DynA (1–17), and Substance P (E) were not associated with any treatment-induced changes. Scale bar
=2 mm.
doi:10.1371/journal.pone.0025653.g007
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quantitative measurement of neuropeptide levels, just as MALDI
MS without the proper standard dilution curve can only
approximate quantitation. Antibody specificity is a major issue
particularly for neuropeptide analysis, however, by comparing
immunoreactivity or peak intensity between the lesioned and the
corresponding intact control side it is possible to obtain a quite
reliable estimation of relative changes in peptide abundance. In
this study the particular DynB antibody has been extensively
validated and displays no cross-reactivity to other dynorphin
peptides (19). Taken together with the observation of the close
correlation between the dynorphin B peak intensity from MALDI
IMS and dynorphin B immunoreactivity in the same animals
(Fig. 8C; p,0.05, R=0.73) present convincing evidence that the
dynorphin B neuropeptide levels are increased in animals with
severe dyskinesia.
In order to measure not only the levels of neuroactive peptide by
MALDI IMS but also dynorphin metabolites, the animals were
Figure 9. MALDI IMS of striatal sections reveal loss of dynorphins in Pdyn -/- knockout mice. (A) Substance P and dynorphin peptides are
mainly localized to the nucleus accumbens and ventral pallidum of wild type (wt) normal control mice (top panel), whereas no dynorphin signal can
be detected in the Pdyn-/- knockout mouse striatum (corresponding bottom panel). Enkephalin peptide PEnk(220–229) is also unaffected in the
Pdyn-/- knockout mouse striatum. The intensity scalebars were set to the same absolute value in ion images from both knockout and control mice.
(B) The loss of dynorphins, but not substance P and PEnk (220–229), in Pdyn-/- knockout mouse compared with wild type controls is evident by the
average mass spectra from nucleus accumbens. Scale bar =2 mm.
doi:10.1371/journal.pone.0025653.g009
Figure 8. Immunohistochemistry of dynorphin B. (A) Immunohistochemical localization of DynB display higher immunolabeling of DynB-
positive axons predominantly in the lateral SN of high dyskinetic animals (arrow). (B) Semi-quantization of DynB optical density measurements show
elevated immunoreactivity in the lateral tier of SN. Values are expressed as mean % OD of intact SN 6 SEM (p,0.001 HD vs. LD, HD vs. LC). (C) A linear
correlation between the Dyn B peak intensity and the corresponding optical density of Dyn B immunoreactivity was observed. Scale bar =2 mm.
doi:10.1371/journal.pone.0025653.g008
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when the rats exhibit most dyskinesia (Fig. 2B). In contrast to most
neurotransmitters, the opioid peptides are not recycled and are
inactivated by proteases or converted to other bioactive peptide
products [37]. The main metabolite detected in this study was
Leu-Enk-Arg that displayed high peak intensities in the lateral SN
and a strong correlation with LID. MALDI IMS offers the ability
to reveal regional overlaps of protein localization by means of
visualization of several peaks and their spatial distribution
concurrently. Visualizing both Leu-Enk-Arg and Dyn B revealed
a striking site-specific expression with high Leu-Enk-Arg in areas
where Dyn B peak intensities were low (Fig. 7A). A tantalizing
explanation suggests that dynorphin B has been released in these
areas, followed by metabolic conversion to Leu-Enk-Arg by for
example the dynorphin-converting enzyme [38]. In addition, the
regional localization in nigra corresponds to striatonigral efferents
from the lateral, but not medial striatum [16]. The possible
conversion of Dyn B to Leu-Enk-Arg is highly interesting since the
cleavage of Dyn B into Leu-Enk-Arg enhance the receptor binding
specificity to delta opioid receptors [39]. Indeed, Leu-Enk-Arg is
one of the main metabolites of synthetic Dyn B as detected in
substantia nigra enzyme extracts [40]. The Leu-Enk-Arg peptide
could be derived from the first 6 amino acids of several
dynorphins, including aNeo, Dyn A(1–17), Dyn A(1–8) and Dyn
B. The seventh amino acid differentiate between aNeo(1–7;
YGGFLRK) and Leu-Enk-Arg-Arg (YGGFLRR) derived from
either Dyn A(1–7) and/or Dyn B(1–7), both of which displayed
elevations in high-dyskinetic animals. Taken together, this suggests
that both Dyn B and aNeo are metabolized through cleavage into
Leu-Enk-Arg (Fig. 10). Proteolytic degradation of samples is
always a major concern in proteomic studies and indeed it has
been shown that prolonged dissection times promote the
degradation of dynorphins [41]. Several nigral peptide ion peaks
correspond to the removal of the initial tyrosine that is important
for opioid receptor binding and activation (Supplemental Fig. S2).
Contrary to what was observed in the striatum, none of the des-
tyrosine dynorphin peptides were affected by L-DOPA or
associated with dyskinesia[42]. In the present study no other
peaks corresponding to a step-wise amino acid removal from the
either N- or C-terminal end of Dyn B or aNeo, suggesting that
general proteolysis was minimal.
Clinical studies have suggested that an early initiation of L-
DOPA- treatment in PD would relieve PD symptoms beyond the
immediate effect of L-DOPA repletion and that this long-duration
motor improvement is sustained for hours to days after cessation of
L-DOPA treatment [43,44,45]. Different mechanisms have been
suggested from L-DOPA-induced elevations of GDNF and BDNF
to a neuroprotective role of L-DOPA itself, however so far we have
not had an animal model in which to study such compensatory
mechanisms. In this study, a worsening of ‘‘PD symptoms’’ was
detected as an increase in left forelimb asymmetry in untreated
lesion control animals over time. By contrast, this worsening was
not seen in L-DOPA-treated animals and in low-dyskinetic
animals this worsening was not only prevented but slightly
reversed (Fig. 2D). We propose that differentiating between low-
and high-dyskinetic animals will allow us to study the molecular
mechanisms underlying the long-duration motor improvement in
the rat model of LID in PD. L-DOPA treatment was initiated 3
weeks after DA-denervation, which is relatively early and thus the
effect on parkinsonian forelimb use might reflect an early
compensatory mechanism in form of protection of DA-cell
degeneration possibly through a non-opiate receptor-mediated
effect of dynorphins on nigral cells [46,47].
L-DOPA-induced dyskinesia in patients with PD has been
linked to elevated preproenkephalin (PPE-A) and PDyn mRNA
levels in the striatum [48,49,50]. Especially high striatal PDyn
mRNA levels have been strongly associated with LID in animal
models of dyskinesias and PD, including primates, monkeys and
Figure 10. Schematic overview of peptides derived from Prodynorphin observed in SN. Peptides in bold were upregulated in high-
dyskinetic animals. Peptides in italic were detected in this study but showed no treatment-related changes. The Leu-Enk-Arg peptide could be
derived from the first 6 amino acids of several dynorphins, including aNeo, Dyn A(1–17), Dyn A(1–8) and Dyn B.
doi:10.1371/journal.pone.0025653.g010
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proposed to reflect an increased activity of striatonigral neurons
of the direct basal ganglia pathway in dyskinesia [52]. In line with
this, antisense-mediated fosB knockdown was paralleled with a
reduction in PDyn mRNA levels and blocked LID development
over time [53]. However, until now the identity of what
prodynorphin peptide products were unknown and insight into
opioid transmission in LID was mainly based on receptor-binding
studies. The endogenous dynorphins mainly display high affinity
to the kappa opioid receptor (KOP), but can also interact with the
other classical opioid receptors mu (MOP) and delta (DOP) with
slightly lower binding affinities [54,55]. Receptor binding studies
have suggested activation of both KOP and MOP receptors in the
substantia nigra of rat and monkey models of LID in PD [56,57].
In both studies a significant negative correlation between
dyskinesia and KOP and MOP receptor-binding in basal ganglia
output structures indicated increased striatonigral opioid trans-
mission in dyskinesia. This is in line with the results of the present
study, since although all dynorphins display high KOP receptor
binding, both Dyn B and aNeo can interact with the other opiate
receptors and in particular aNeo displays the least selectivity being
active in the nanomolar range at both DOPr and MOPr [39,58].
Clinical and preclinical studies of the effects of opioid agonists
and antagonists on LID have shown contradictory results[51].
Systemic administration of non-selective opiate antagonists has
been associated with both increases and decreases of LID in
parkinsonian monkeys and patients [8,9,10,12,59]. Specific kappa-
agonist U50-488 has shown promising anti-dyskinetic effects in
both rat and monkey models of PD, however in monkey the anti-
parkinsonian symptomatic relief by L-DOPA was abolished and
furthermore, severe side effects in form of sedation and vomiting
reduced the therapeutically value [6,7]. The present study
indicates that prodynorphin processing in the striatonigral
projection neurons leads to peptides that are not the most effective
kappa agonists and may result in abnormal signaling through the
delta and mu opioid receptor instead. Indeed, both DOPr and
MOPr-antagonists attenuate LID in the MPTP-lesioned marmoset
[5].
For the first time it has been possible to demonstrate that
chronic intermittent L-DOPA at a dose regime that is known to
cause an upregulation of striatal PDyn mRNA levels is also
associated with a concomitant elevation in dynorphin B and alpha-
neoendorphin peptide levels in one of the basal ganglia output
structures, the substantia nigra. Furthermore, using imaging mass
spectrometry it was possible to localize the predominant area
affected to the lateral part of SN, where the two opioid peptide
peak intensities were most strongly associated with the severity of
L-DOPA-induced dyskinesia. By contrast, the Dyn A-related
peptides, which have the highest affinity to KOP receptors, were
detected at low levels but did not show any treatment- or LID-
associated changes. The main dynorphin metabolite detected,
Leu-Enk-Arg that has even less affinity to KOP receptors, also
displayed a strong correlation between the peak intensities in the
lateral SN and LID severity. So far no subtype-selective opioid
antagonists have been evaluated in PD patients with LID;
however, our data suggest that both DOP and MOP receptor
specific antagonist could be of potential interest.
Supporting Information
Figure S1 MS/MS analyses of dynorphins. (A) Examples
of fragmentation spectra of endogenous dynorphin B and (B)
alpha-neoendorphin. Similar results were obtained for Leu-Enk,
Leu-Enk-Arg, dynorphin A(10–17), and alpha-neoendorphin (2–
8). For peptide identification the database search was made with
no enzyme/unspecific cleavage, and no fixed or variable
modifications.
(TIF)
Figure S2 MALDI IMS of putative des-tyrosine dynor-
phins. (A) Composite MALDI IMS ion images from one single
section of a high dyskinetic animal reveal an overlap in regional
distribution of DynA(1–8), visualized in green, and its potential
des-tyrosine fragment DynA(2–8) in red.(B) A similar pattern was
observed for aNeo(green) and its des-tyrosine fragment aNeo(2–10)
(red), and(C) DynB (green) and its corresponding des-tyrosine
peptide DynB(2–13) (red), however no treatment-induced changes
were detected for the des-tyrosine peptides. Des-tyrosine aNeo (2–
10) has been identified by LC-MS/MS. Scale bar=2 mm.
(TIF)
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